ArticleImmuno-oncology technology2026
Quality of life and care experience in durable responders to immune checkpoint inhibitors for advanced or metastatic NSCLC or melanoma.
N Girard et al.PubMed ↗Full text ↗Publisher ↗
No numbers read from the abstract.